Background
Methods
Study design
Study sites
Study population
Treatment
Patient follow-up
Laboratory procedures
Data analysis
Results
Baseline characteristics
Characteristic | NWMH | WRH | SMH | BMH | BGH | HMH | TAGH | LEKMH | EWP | TOTAL |
---|---|---|---|---|---|---|---|---|---|---|
n = 55 | n = 51 | n = 54 | n = 63 | n = 62 | n = 61 | n = 61 | n = 23 | n = 62 | N = 492 | |
Male/female | 24/31 | 27/24 | 28/26 | 30/33 | 25/37 | 33/28 | 38/23 | 7/16 | 32/30 | 244/248 |
Age group | ||||||||||
< 5 years (%) | 21 (38.2) | 37 (72.5) | 35 (64.8) | 44 (69.8) | 32 (51.6) | 37 (60.7) | 34 (55.7) | 14 (60.9) | 29 (46.8) | 283 (57.5) |
5–9 years | 34 | 14 | 19 | 19 | 30 | 24 | 27 | 9 | 33 | 209 |
Weight (kg) | ||||||||||
Mean weight (sd) | 17.9 (6.0) | 14.4 (5.3) | 16.1 (5.1) | 14.7 (4.9) | 16.0 (6.1) | 15.5 (4.6) | 16.0 (5.4) | 17.6 (5.5) | 17.2 (6.0) | 16.1 (5.5) |
Range (min, max) | 8.0, 30.0 | 7.1, 27.0 | 7.0, 27.0 | 6.6, 35.0 | 6.1, 32.3 | 8.0, 27.0 | 7.2, 29.0 | 9.0, 29.4 | 6.7, 30.0 | 6.1, 35.0 |
Axillary temperature in °C | ||||||||||
Mean temperature (sd) | 38.7 (0.8) | 37.9 (1.0) | 37.7 (0.9) | 38.2 (1.1) | 37.7 (1.1) | 38.0 (1.0) | 38.6 (1.1) | 38.1 (1.2) | 38.2 (1.1) | 38.1 (1.1) |
Range (min, max) | 37.5, 40.4 | 36.0, 39.8 | 36.0, 39.8 | 35.4, 40.3 | 35.2, 39.7 | 36.2, 40.1 | 36.0, 40.4 | 35.9, 39.7 | 35.8, 40.5 | 35.2, 40.5 |
Asexual parasitaemia/µl | ||||||||||
Geometric mean | 53,441 | 42,754 | 31,815 | 39,961 | 29,423 | 36,917 | 9039 | 18,747 | 41,089 | 31,119 |
Range (min, max) | 3200, 217,182 | 1200, 247,040 | 1391, 208,000 | 2365, 246,227 | 1822, 146,686 | 1747, 206,502 | 1000, 163,343 | 3248, 101,423 | 1340, 229,410 | 1000, 247,040 |
Gametocytaemia (%) | 0.0 | 2.0 | 0.0 | 0.0 | 0.0 | 1.6 | 1.6 | 0.0 | 3.2 | 1.0 |
Haemoglobin level in g/dl | ||||||||||
Mean (sd) | 9.6 (1.6) | 8.8 (1.8) | 10.0 (1.7) | 10.3 (2.0) | 10.8 (1.9) | 10.1 (1.4) | 10.5 (1.6) | 9.9 (1.7) | 10.8 (1.4) | 10.1 (1.8) |
Range (min, max) | 6.0, 12.7 | 5.4, 12.8 | 6.0, 12.9 | 6.4, 16.0 | 5.1, 13.9 | 6.5, 13.3 | 6.1, 13.1 | 7.1, 12.2 | 7.2, 13.9 | 5.1, 16.0 |
Characteristic | NWMH | YMH | SMH | BMH | BGH | HMH | TAGH | EWP | TOTAL |
---|---|---|---|---|---|---|---|---|---|
n = 58 | n = 60 | n = 43 | n = 63 | n = 63 | n = 60 | n = 58 | n = 67 | N = 472 | |
Male/female | 29/29 | 32/28 | 20/23 | 34/29 | 32/31 | 33/27 | 32/26 | 37/30 | 249/223 |
Age group | |||||||||
< 5 years (%) | 33 (56.9) | 33 (55.0) | 32 (74.4) | 45 (71.4) | 34 (54.0) | 19 (31.7) | 37 (63.8) | 34 (50.7) | 267 (56.6) |
5–9 years | 25 | 27 | 11 | 18 | 29 | 41 | 21 | 33 | 205 |
Weight (kg) | |||||||||
Mean weight (sd) | 15.9 (5.2) | 14.0 (6.0) | 15.4 (4.7) | 14.1 (4.3) | 17.3 (6.9) | 17.8 (5.3) | 16.2 (5.9) | 17.1 (5.8) | 16.0 (5.7) |
Range (min, max) | 8.0, 29.0 | 5.0, 35.0 | 8.0, 30.0 | 8.0, 26.0 | 7.0, 35.0 | 7.8, 32.0 | 6.2, 33.0 | 7.0, 40.0 | 5.0, 40.0 |
Axillary temperature in °C | |||||||||
Mean temperature (sd) | 38.5 (1.2) | 37.6 (0.9) | 37.1 (0.8) | 38.3 (1.2) | 38.0 (1.3) | 38.2 (0.9) | 38.3 (1.0) | 38.0 (1.1) | 38.0 (1.1) |
Range (min, max) | 36.1, 40.5 | 36.0, 39.5 | 35.5, 39.8 | 35.7, 41.5 | 35.8, 40.8 | 37.0, 40.8 | 35.7, 40.2 | 36.1, 40.7 | 35.5, 41.5 |
Asexual parasitaemia/µl | |||||||||
Geometric mean | 14,454 | 36,433 | 23,957 | 21,975 | 54,373 | 40,198 | 2941 | 44,238 | 23,534 |
Range (min, max) | 2200, 183,680 | 1035, 218,877 | 1040, 211,400 | 2528, 215,615 | 5963, 226,615 | 5040, 24,783 | 1120, 65,800 | 1200, 249,960 | 1035, 249,960 |
Gametocytaemia (%) | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 |
Haemoglobin level in g/dl | |||||||||
Mean (sd) | 9.5 (1.6) | 9.0 (1.5) | 10.4 (1.2) | 9.7 (1.3) | 10.4 (1.4) | 10.2 (1.1) | 10.9 (1.8) | 10.8 (1.7) | 10.1 (1.6) |
Range (min, max) | 6.2, 11.9 | 5.4, 13.4 | 7.3, 12.5 | 6.4, 13.0 | 7.2, 13.8 | 7.1, 12.3 | 7.7, 15.2 | 6.5, 16.6 | 5.4, 16.6 |
Primary outcomes
Antimalarial drug | Treatment outcome | Sentinel site | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
WRH | NWMH | YMH | SMH | BMH | BGH | HMH | TAGH | LEKMH | EWP | |||
AS–AQ | n = 51 | n = 55 | n = 0 | n = 54 | n = 63 | n = 62 | n = 61 | n = 61 | n = 23 | n = 62 | N = 492 | |
ETF | 0 | 1 | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
LCF | 0 | 0 | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
LPF | 0 | 0 | – | 0 | 1 | 1 | 0 | 0 | 0 | 4 | 6 | |
ACPR | 45 | 54 | – | 51 | 62 | 58 | 58 | 60 | 20 | 58 | 466 | |
LFU | 5 | 0 | – | 3 | 0 | 3 | 3 | 1 | 3 | 0 | 18 | |
WTH | 1 | 0 | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Antimalarial drug | Treatment outcome | Sentinel site | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
WRH | NWMH | YMH | SMH | BMH | BGH | HMH | TAGH | LEKMH | EWP | |||
AL | n = 0 | n = 58 | n = 60 | n = 43 | n = 63 | n = 63 | n = 60 | n = 58 | n = 0 | n = 67 | N = 472 | |
ETF | – | 0 | 0 | 1 | 0 | 0 | 0 | 2 | – | 0 | 3 | |
LCF | – | 0 | 0 | 0 | 1 | 1 | 0 | 0 | – | 0 | 2 | |
LPF | – | 5 | 3 | 3 | 3 | 1 | 0 | 12 | – | 9 | 36 | |
ACPR | – | 53 | 54 | 39 | 59 | 57 | 47 | 42 | – | 54 | 405 | |
LFU | – | 0 | 0 | 0 | 0 | 2 | 13 | 2 | – | 1 | 18 | |
WTH | – | 0 | 3 | 0 | 0 | 2 | 0 | 0 | – | 3 | 8 |
Site | PCR-uncorrected | PCR-corrected | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AS–AQ | AL | AS–AQ | AL | |||||||||||||
PP | KM | PP | KM | PP | KM | PP | KM | |||||||||
n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | |
NWMH | 55 | 98.2 (90.3–100.0) | 55 | 98.2 (87.8–99.7) | 58 | 91.4 (81.0–97.1) | 58 | 91.4 (80.5–96.3) | 55 | 98.2 (90.3–100.0) | 55 | 98.2 (87.8–99.7) | 54 | 98.1 (90.1–100.0) | 54 | 98.1 (87.6–99.7) |
WRH | 45 | 100.0 (92.1–) | 51 | 100.0 (n/a) | – | – | – | – | 45 | 100.0 (92.1–) | 51 | 100.0 (n/a) | – | – | – | – |
YMH | – | – | – | – | 57 | 94.7 (85.4–98.9) | 60 | 94.7 (84.6–98.3) | – | – | – | – | 56 | 96.4 (87.7–99.6) | 59 | 96.4 (86.5–99.1) |
SMH | 51 | 100.0 (93.0–) | 54 | 100.0 (n/a) | 43 | 90.7 (77.9–97.4) | 43 | 90.7 (77.1–96.4) | 51 | 100.0 (93.0–) | 54 | 100.0 (n/a) | 42 | 92.9 (80.5–98.5) | 42 | 92.9 (79.5–97.6) |
BMH | 63 | 98.4 (91.5–100.0) | 63 | 98.4 (89.3–99.8) | 63 | 93.7 (84.5–98.2) | 63 | 93.7 (84.0–97.6) | 62 | 100.0 (94.2–) | 63 | 100.0 (n/a) | 61 | 96.7 (88.7–99.6) | 61 | 96.7 (87.5–99.2) |
BGH | 59 | 98.3 (90.9–100.0) | 62 | 98.3 (88.6–99.8) | 59 | 96.6 (88.3–99.6) | 63 | 96.6 (87.1–99.1) | 59 | 98.3 (90.0–100.0) | 62 | 98.3 (88.6–99.8) | 57 | 100.0 (93.7–) | 61 | 100.0 (n/a) |
HMH | 58 | 100.0 (93.8–) | 61 | 100.0 (n/a) | 47 | 100.0 (92.5–) | 60 | 100.0 (n/a) | 58 | 100.0 (93.8–) | 61 | 100.0 (n/a) | 47 | 100.0 (92.5–) | 60 | 100.0 (n/a) |
TAGH | 60 | 100.0 (94.0–) | 61 | 100.00 (n/a) | 56 | 75.0 (61.6–85.6) | 58 | 75.4 (62.0–84.6) | 60 | 100.0 (94.0–) | 61 | 100.0 (n/a) | 46 | 91.3 (79.2–97.6) | 53 | 92.2 (80.4–97.0) |
LEKMH | 20 | 100.0 (83.2–) | 23 | 100.0 (n/a) | – | – | – | – | 20 | 100.0 (83.2–) | 23 | 100.0 (n/a) | – | – | – | – |
EWP | 62 | 93.5 (84.3–98.2) | 62 | 93.5 (83.7–97.5) | 63 | 85.7 (74.6–93.3) | 67 | 85.7 (74.3–92.3) | 60 | 96.7 (88.5–99.6) | 62 | 96.8 (87.7–99.2) | 59 | 91.5 (81.3–97.2) | 65 | 91.7 (81.2–96.5) |
Overall | 473 | 98.5 (96.8–99.3) | 492 | 98.5 (96.9–99.3) | 446 | 90.8 (87.6–93.2) | 472 | 90.9 (87.9–93.2) | 470 | 99.2 (97.7–99.7) | 492 | 99.2 (97.8–99.7) | 422 | 96.0 (93.5–97.6) | 455 | 96.1 (93.8–97.5) |
Secondary outcomes
Antimalarial drug | Site | Mean Hb (sd) | p-value | |
---|---|---|---|---|
Day 0 | Day 28 | |||
AS–AQ | WRH | 8.8 (1.8) | 9.6 (1.2) | 0.015 |
NWMH | 9.6 (1.6) | 9.9 (1.2) | 0.268 | |
SMH | 10.0 (1.7) | 11.0 (1.0) | 0.008 | |
BMH | 10.3 (2.0) | 11.1 (1.6) | 0.015 | |
BGH | 10.9 (1.9) | 11.7 (1.1) | 0.006 | |
HMH | 10.1 (1.4) | 11.5 (0.9) | < 0.001 | |
TAGH | 10.5 (1.6) | 11.2 (1.2) | 0.015 | |
LEKMH | 9.9 (1.7) | 11.5 (0.8) | < 0.001 | |
EWP | 10.8 (1.4) | 12.1 (1.7) | < 0.001 | |
Overall | 10.1 (1.8) | 11.1 (1.5) | < 0.001 | |
AL | NWMH | 9.5 (1.6) | 10.6 (1.2) | 0.001 |
YMH | 9.0 (1.5) | 10.4 (1.5) | < 0.001 | |
SMH | 10.5 (1.2) | 11.3 (0.8) | 0.001 | |
BMH | 9.7 (1.3) | 10.8 (0.8) | < 0.001 | |
BGH | 10.4 (1.4) | 11.4 (1.1) | < 0.001 | |
HMH | 10.2 (1.1) | 10.9 (0.9) | 0.001 | |
TAGH | 10.9 (1.8) | 11.4 (1.4) | 0.103 | |
EWP | 10.8 (1.7) | 10.9 (1.1) | 0.693 | |
Overall | 10.1 (1.6) | 10.9 (1.2) | < 0.001 |